Engineers Gate Manager’s C4 Therapeutics CCCC Stock Holding History

Engineers Gate Manager’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,416	Closed	-$46.6K	–	2216
2025 Q4	$46.6K	Buy	24,416 +8,130	+50%	+$19.3K	﹤0.01%	1983
2025 Q3	$36.2K	Buy	16,286 +5,868	+56%	+$14.1K	﹤0.01%	2080
2025 Q2	$14.9K	Buy	+10,418	New	+$15.2K	﹤0.01%	2102
2025 Q1	–	Sell	-25,555	Closed	-$92K	–	2203
2024 Q4	$92K	Buy	25,555 +2,742	+12%	+$13.6K	﹤0.01%	2010
2024 Q3	$130K	Buy	+22,813	New	+$137K	﹤0.01%	1886
2024 Q2	–	Sell	-104,367	Closed	-$853K	–	1950
2024 Q1	$853K	Buy	+104,367	New	+$809K	0.02%	920
2023 Q3	–	Sell	-10,900	Closed	-$30K	–	1815
2023 Q2	$30K	Buy	+10,900	New	+$35K	﹤0.01%	1652

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Engineers Gate Manager's CCCC Position: Q1 2026 in Review

Engineers Gate Manager sold out of C4 Therapeutics (CCCC) in Q1 2026, closing a stake of 24,416 shares — an estimated $46.6K sold.

Engineers Gate Manager first reported a position in CCCC in Q2 2023 and held it in 7 quarters. The position peaked at $853K in Q1 2024. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

Engineers Gate Manager reported no remaining C4 Therapeutics position as of Q1 2026 after selling out during the quarter.
Engineers Gate Manager sold 24,416 C4 Therapeutics shares in Q1 2026, an estimated $46.6K.
Engineers Gate Manager first reported a position in C4 Therapeutics in Q2 2023 and held it in 7 quarters.
Engineers Gate Manager's C4 Therapeutics position peaked at $853K in Q1 2024.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.